Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX

Coronary Artery Disease Clinical Trial

Official title:

Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis in the Aortic Position, Model 3300TFX

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01171625
• Other study ID #: 2007-08
• Status: Completed
• Phase: N/A
• Start date: October 2007
• Est. completion date: September 2018

Study information

• Verified date: April 2020
• Source: Edwards Lifesciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards PERIMOUNT Magna Ease Valves in patients undergoing aortic valve replacement with or without concomitant procedures requiring cardiopulmonary bypass.

Description:

This is a prospective, single-arm, multi-center, interventional study to be conducted in the US and outside the US (OUS). This study will enroll a minimum of 225 patients implanted with the study valve in order to achieve 101 aortic valve replacement subjects each followed for a minimum of 8 years. The study will include male and female patients, 18 years or older, requiring replacement for a diseased, damaged or malfunctioning natural or prosthetic aortic valve. Patients will be followed and assessed after implant at discharge, 6 months, one year, and annually for a minimum of 8 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 283
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient requires, as indicated in the preoperative evaluation, a replacement aortic valve.

2. The patient is an average or better operative risk.

3. The patient is geographically stable and agrees to attend follow-up assessments at the hospital of surgical services for at least 8 years.

4. The patient is 18 years or older.

5. The patient has signed and dated the subject informed consent form prior to surgery.

Exclusion Criteria:

1. The patient has any known non-cardiac life-threatening disease, which will limit the patient's life expectancy below 1 year.

2. The patient presents with active endocarditis within the last 3 months.

3. The patient has an abnormal calcium metabolism (e.g., chronic renal failure, hyperparathyroidism).

4. The patient has an aneurismal aortic degenerative condition (e.g., cystic medial necrosis, Marfan's syndrome).

5. The patient is pregnant or lactating.

6. The patient is an intravenous drug abuser.

7. The patient is currently a prison inmate.

8. The patient is currently participating in a study of an investigational drug or device.

9. The patient requires replacement of a native or prosthetic mitral, tricuspid or pulmonic valve.

10. The patient requires a repair of the mitral or tricuspid valve with the use of an annuloplasty device.

11. The patient was previously enrolled in the study.

12. The patient had a prior mitral, tricuspid or pulmonic valve surgery, which included implantation of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ.

Related Conditions & MeSH terms

• Aortic Valve Disorder
• Aortic Valve Insufficiency
• Aortic Valve Stenosis
• Coronary Artery Disease
• Heart Failure

Intervention

Device:
• Implantation of CEP Magna Ease Model 3300TFX
Heart Valve Surgery

Locations

Country	Name	City	State
Austria	Universitatslinik fur Chirurgie	Innsbruck
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	St. Paul's Hospital	Vancouver
Germany	Klinik fur Herz-, Thorax-, Transplantations- und Gefabchirurgie	Hannover
Germany	Liknik fur Herz und BefaBchirurgie Im Deuschen Herzzentrum	Munich	Lazarettstr
Spain	Hospital Peutra de Hierro	San Martin de Porres 4	Madrid
United Kingdom	Blackpool Victoria Hospital	Blackpool	Lancashire
United Kingdom	Papworth Hospital NHS foundation Trust	Papworth Everard	Cambridge
United States	Cooper University Hospital	Camden	New Jersey
United States	Morristown Memorial Hospital	Morristown	New Jersey
United States	Providence Heart & Vascular Institute	Portland	Oregon
United States	Mercy General Hospital	Sacramento	California
United States	St. Marks Hospital	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Edwards Lifesciences

Countries where clinical trial is conducted

United States,  Austria,  Canada,  Germany,  Spain,  United Kingdom, 

References & Publications (1)

Wahlers TCW, Andreas M, Rahmanian P, Candolfi P, Zemanova B, Giot C, Ferrari E, Laufer G. Outcomes of a Rapid Deployment Aortic Valve Versus Its Conventional Counterpart: A Propensity-Matched Analysis. Innovations (Phila). 2018 May/Jun;13(3):177-183. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subject's Percentage of Long Term Safety Performance	Long term safety performance will be evaluated by comparing the linearized yearly rates to the objective performance criteria (OPC) referenced in the Food and Drug Administration (FDA) 1994 Draft Heart Valve Guidance.; Expressed as the Number of late events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).	31 days through 8 years post-implant
Primary	Number of Subject's in NYHA Functional Class I or II at 8 Year Post-Implant	The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.; Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).; Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).	8 years post-implant
Primary	Subject's New York Heart Association (NYHA) Functional Class at 8 Years Post-Implant Compared to Baseline	The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.; Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).; Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).; Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.; Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.	8 Years post-implant
Secondary	Percent of Early Adverse Events	Number of early adverse events occurring within 30 days of procedure divided by the number of enrolled subjects times 100.	Events occurring within 30 days of procedure
Secondary	Percentage of Late Adverse Events	Number of late events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).	Events occurring >= 31 days and up through 8 years post-implant
Secondary	Percent of Subjects With Freedom From Serious Adverse Events (SAE) Post-implant > 30 Days	Subject's freedom from Serious Adverse Events at > 30 days post-implant. Time to events were estimated by Kaplan-Meier method.	1 Year, 2 Years, 3 Years, 4 Years, 5 Years, 6 Years, 7 Years, and 8 Years post-implant
Secondary	Subject's Average Peak Systolic Gradient (mmHg) Measurements at 8 Years Post-implant	Peak systolic gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Mean Systolic Gradient (mmHg) Measurements at 8 Years Post-implant.	Mean systolic gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Mean gradient values depend on the size and type of valve. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Effective Orifice Area Measurements at 8 Years Post-implant.	Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Effective Orifice Area Index (EOAI) Measurements at 8 Years Post-implant.	Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Performance Index Measurements at 8 Years Post-implant.	Performance index is defined as the subject's effective orifice area (the cross-sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Cardiac Output Measurements at 8 Years Post-implant.	The amount of blood the heart pumps through the circulatory system in a minute. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Average Cardiac Index Measurements at 8 Years Post-implant.	Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area (BSA), thus relating heart performance to the size of the individual. The data summary will be stratified by valve size.	8 years post-implant
Secondary	Subject's Amount of Aortic Valvular Regurgitation at 8 Years Post-Implant.	Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.	8 years post-implant
Secondary	Subject's Average White Blood Cell Count Measurement Over Time.	Laboratory analysis of White Blood Cell Count on blood drawn from subject; WBC fight infection.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Red Blood Cells Count Over Time.	Laboratory Analysis of Red Blood Cell (RBC) Count on blood drawn from subjects; RBC carry oxygen.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Hematocrit Percentage Over Time.	Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the fluid component (plasma) in the blood.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Hemoglobin Count Over Time.	Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Platelet Count Over Time.	Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Serum Lactate Dehydrogenase (LDH) Over Time.	Laboratory Analysis of Serum Lactate Dehydrogenase on blood drawn from subjects; The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Haptoglobin Measurement Over Time.	Laboratory Analysis of haptoglobin on blood drawn from subjects; haptoglobin is a protein produced by the liver.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Reticulocytes Percentage Over Time.	Laboratory Analysis of reticulocytes on blood drawn from subjects. Reticulocytes are newly produced immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood.	6 months and annually for 8 years post-implant
Secondary	Subject's Average Score on the EQ-5D- Quality of Life Questionnaire at Baseline and 6 Months Post-Implant.	The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from a minimum of 0 and a maximum of 100 where zero is the 'worst state imaginable' and 100 is the 'best state imaginable'.	Baseline and 6 Months Post-Implant

External Links

•   Measure of Health Status Survey (EQ-5D)
•   New York Heart Association Classification